For stage III and IV melanoma patients receiving CD1c+ DC-based vaccinations, the presence of CD1c+CD14+ DCs (DC3) in vaccine preparations suppresses CD4+ T cells (3, 4). This evidence concerns the gene CD1C and melanoma.